NSCLC represents 80% of lung cancer cases and is the leading cause of cancer-related mortality globally. This designation is ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Friday, August 15, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily ...

With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird ...

Bristol Myers Squibb BMY -1.9% (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is undervalued, as ...

The American College of Cardiology has established the Connect-HCM digital registry to broaden understanding of, improve access to care for, hypertrophic cardiomyopathy, one of the most common genetic ...